Offering a New Model of Primary Care
Founded in 2014, Aledade offers a new model of primary care that puts physicians back where they should be: quarterbacking their patients’ health care. Aledade has grown rapidly and currently partners with more than 430+ practices with more than 650,000 patients across 24 states to help them deliver seamless, affordable, high-quality care.
Experts and Leaders
Our executive team has been on the forefront of health care policy and technology innovation for the past two decades and are recognized leaders in the field. We bring an insider’s perspective to a complex and changing health care landscape.
Where We Are
Aledade’s Value Based Care Network
Aledade’s rapidly expanding network covers more than 650,000 patients in 24 states. Learn about where we are and where we’re going.
Joining the Team
Aledade is looking for experienced, dedicated employees who share our vision and passion for a new model of primary care. Visit our Careers page to learn more about employment opportunities and what it’s like to work at Aledade.
Our Board of Directors
In addition to Aledade CEO and Board Chair, Dr. Farzad Mostashari, Aledade’s Board Members include Dr. Bob Kocher, Dr. Mark McClellan, Julie Sunderland, and Jim Manzi.
Dr. Bob Kocher
Dr. Bob Kocher is a Partner at Venrock and focuses on healthcare IT and services investments. Additionally, he is a Consulting Professor at Stanford University School of Medicine, Senior Fellow and Advisory Board Member at the Leonard D. Schaeffer Center for Health Policy and Economics at USC, and Guest Scholar at the Brookings Institution Engleberg Center for Health Reform. Prior to Venrock, Bob served in the Obama Administration as Special Assistant to the President for Healthcare and Economic Policy on the National Economic Council. He also co-founded the Health Data Initiative with Todd Park, a joint effort of HHS and the Institute of Medicine, to release healthcare data to spur private sector innovation to improve healthcare cost and quality. Bob received undergraduate degrees from the University of Washington and a medical degree from George Washington University.
Dr. Patrick H. Conway
Dr. Patrick H. Conway, joined Blue Cross and Blue Shield of North Carolina in 2017 as President and CEO. Conway most recently served as Deputy Administrator for Innovation and Quality at the federal Centers for Medicare and Medicaid Services (CMS). As the most senior non-political leader at CMS, he worked in both Republican and Democratic administrations and is considered one of the driving forces behind the national movement to value-based care, with health care payments tied to quality and innovation. A respected leader, innovator and clinician, Conway was elected to the National Academy of Medicine (NAM) in 2014. He is a practicing pediatric hospitalist and was selected as a master of hospital
medicine from the Society of Hospital Medicine.
Julie Sunderland is a Managing Director of Biomatics Capital, a new $200mm venture capital fund investing in breakthrough science and technology that will transform the practice of medicine and delivery of healthcare, especially in the genomics and digital health sectors. Until recently, Ms. Sunderland was the Director of Program Related Investments for the Bill & Melinda Gates Foundation, where she was responsible for managing the foundation’s $1.5 billion program-related investment (PRI) pool which focuses on strategic investments in global health, global development, and US education. Ms. Sunderland founded the PRI program in 2009 as a $400 million pilot and grew the portfolio to 50 investments comprising a range of investment structures (equity, loans, guaranties, funds), sectors (biotech, health commodities, health delivery, agriculture, digital payments, charter schools, education technology), and geographies (US, Europe, Africa, India, China). She built and led a team of 10 investment professionals and chaired the foundation’s investment committee that reviews all program-related investments undertaken by the foundation. Ms. Sunderland holds a BA from Harvard University, an MBA from Wharton Business School and an MA from Johns Hopkins School of Advanced International Studies.
Jim Manzi is a founder and partner of Foundry.ai, a technology studio focused on conceptualizing and building AI application software businesses. He was founder, CEO and Chairman of Applied Predictive Technologies, which became the world’s largest purely cloud-based predictive analytics software company, and was sold to MasterCard in 2015. Previously, he worked at Bell Labs and as a corporate strategy consultant. Jim is the author of several software patents, as well as the 2012 book Uncontrolled, which has been widely reviewed in the New York Times, Wall Street Journal and other national publications. He received a B.S. in mathematics from MIT, and was subsequently awarded a Dean’s Fellowship in statistics to the doctoral program at the Wharton School of the University of Pennsylvania.
Aledade is backed by leading venture capital firms Venrock, ARCH Venture Partners, GV, Biomatics Capital Partners, and the Maryland Venture Fund. An established leader in health IT venture capital, Venrock’s investment is led by Bryan Roberts, lead investor in several health care companies valued at over $1 billion, and Dr. Bob Kocher, former special assistant to President Obama for health care and economic policy. Robert Nelsen, co-founder and managing director of ARCH Venture Partners, and Kristina Burow, managing director, have described Aledade as “uniquely positioned to help lead the U.S. health care system, with primary care physicians at the center of their patients’ care.” Biomatics Capital is a Seattle-based digital health and genomics focused venture capital firm, founded by Boris Nikolic, former chief scientific and technology advisor to Bill Gates, and Julie Sunderland, a former director at the Bill & Melinda Gates Foundation. GV, formerly Google Ventures, is the venture capital arm of Alphabet, Inc. that provides funding to bold new companies that aim to improve lives and change industries. The Maryland Venture Fund is an early-stage, evergreen venture capital fund dedicated to funding and growing the next generate of outstanding businesses in Maryland.